Navigation Links
Arena Pharmaceuticals Announces First Quarter 2008 Financial Results
Date:5/7/2008

ifferences,

if any, in the rates of valvulopathy (as defined by the Food and Drug

Administration, or FDA) in patients treated with lorcaserin and in the

control group did not meet the ESMB's predetermined stopping criteria.

o Announced the initiation of a Phase 1 clinical trial of a second

generation oral niacin receptor agonist intended for the treatment of

atherosclerosis in partnership with Merck & Co., Inc.

o Entered into strategic agreements with Siegfried Ltd primarily related

to the manufacturing of lorcaserin for Arena's planned New Drug

Application submission to the FDA and for commercialization of

lorcaserin after regulatory marketing approval. The agreements include

the purchase of certain drug product manufacturing and packaging

facility assets, including fixtures, equipment, other personal property

and real estate assets, located in Zofingen, Switzerland.

o Reported positive Phase 1a clinical trial results of APD791, Arena's

oral, internally discovered drug candidate intended for the treatment of

arterial thrombosis, and initiated a Phase 1b clinical trial to further

evaluate this drug candidate.

o Announced that initial clinical trial results for APD668, an oral drug

candidate discovered by Arena and being investigated for the treatment

of type 2 diabetes in partnership with Ortho-McNeil Pharmaceutical,

Inc., suggest that the Glucose-Dependent Insulinotropic Receptor, or

GDIR, improves glucose control in patients with type 2 diabetes. Based

on the data from those studies, Ortho-McNeil put APD668 on hold and

advanced a potentially more potent Arena-discovered GDIR agonist into

preclinical development.

Scheduled Earnings Call

Arena will host both a conference call and webcast to discuss the first quarter 2008 financial results and to provide a corporat
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
3. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
4. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
7. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
8. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
10. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
11. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... CARLOS, Calif. , May 28, 2015 /PRNewswire/ ... testing, today announced a study published in ... the Panorama single-nucleotide polymorphism (SNP)-based non-invasive prenatal test ... the first trimester. A study ... that complete molar pregnancies occur in about 1 ...
(Date:5/28/2015)... , May 28, 2015  PDS Biotechnology Corp. ... immunotherapy treatment targeting HPV-16, has generated strong T-cell ... Currently, pre-cervical cancer is treated by surgical removal ... and effective non-surgical alternative. Results show that it ... to recognize, target, and kill precancerous and cancerous ...
(Date:5/28/2015)... , May 28, 2015  GenVec, Inc. (Nasdaq: ... Douglas J. Swirsky , will present a company ... 11 a.m. EDT on Thursday, June 4, 2015. ... Swirsky,s presentation will be available at the following link:  ... on GenVec,s website.  To access, visit www.genvec.com , ...
(Date:5/28/2015)... Glenn Keet, CEO of Clinovo ... EMR/EHR Clinical Data Integration with EDC Systems ” at ... DC on June 14th-18th. , During the presentation, Glenn ... with EDC, and will examine the value of patient ... electronic health records/electronic medical records integration. , The ...
Breaking Biology Technology:First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test 2First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test 3PDS Biotechnology reports positive Phase I clinical trial results in proprietary HPV-Cancer Immunotherapy 2GenVec To Present At The Jefferies Healthcare Conference 2Clinovo Presents at the DIA 2015 51st Annual Meeting in Washington, DC on June 14th-18th 2
... via Single ... Platform, MirixaPro(SM), RESTON, Va. and WASHINGTON, Oct. ... creator of,the Diabetes Ten City Challenge and a partner in the ... that will,deliver all of APhA Foundation,s HealthMapRx commercial programs via,Mirixa. MirixaPro(SM) ...
... Oct. 9 eResearchTechnology,Inc. (eRT), (Nasdaq: ERES ... technology, ePRO and other services to the pharmaceutical,biotechnology, ... will release its 2008 third quarter results for ... 30, 2008 after the market closes.,After the release, ...
... CEL-SCI Corporation,(NYSE: CVM ) announced today ... facility for its lead drug Multikine(R). This dedicated,facility, ... Multikine that,will be used for CEL-SCI,s pivotal Phase ... head and neck cancer patients, and,subsequently for sale ...
Cached Biology Technology:Mirixa Corporation and the APhA Foundation Form Partnership 2Mirixa Corporation and the APhA Foundation Form Partnership 3eResearchTechnology, Inc. to Announce 2008 Third Quarter Results on October 30, 2008 2CEL-SCI Takes Delivery of New Manufacturing Facility 2
(Date:5/14/2015)... , May 14, 2015  Verificient ... identity verification and online remote proctoring, announced ... software-as-a-service (SaaS) company and creator of the ... of the two companies will benefit from ... Canvas. As a fully integrated ...
(Date:5/8/2015)... , May 8, 2015 Synaptics Inc. (NASDAQ: ... today announced that members of the executive management team will ... 43rd Annual Technology, Media and Telecom Conference Date: May ... in Boston, MA Cowen ... 2015 Time: 2:45pm ET Location: The New York Palace Hotel, ...
(Date:4/27/2015)... Apr. 27, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces ... pre-order customers the first week of May, 2015 and ... of May. Gino Pereira , ... for the company as Wocket® enters the consumer market. ...
Breaking Biology News(10 mins):Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Synaptics to Present at Upcoming Investor Conferences 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3
... (BRONX, NY) "It,s in their genes" is a common ... to reach age 100 and beyond. Up until now, ... advantage such as high levels of HDL ("good") cholesterol. But ... Ferkauf Graduate School of Psychology of Yeshiva University ...
... San Diego have discovered that a small dose of a ... and affects their ability to recruit their nestmates to otherwise ... in this week,s issue of the Journal of Experimental ... to bee-pollinated crops and shed light on one of the ...
... in German . , Tobacco: actually pretty bad food ... of wild tobacco ( Nicotiana attenuata ). When this plant grows ... by tobacco hornworm larvae ( Manduca sexta ). This specialist insect ... a defense against its enemies. When researchers from the Max Planck ...
Cached Biology News:'Personality genes' may help account for longevity 2Commonly used pesticide turns honey bees into 'picky eaters' 2Deterring signals: Tobacco plants advertise their defensive readiness to attacking leafhoppers 2Deterring signals: Tobacco plants advertise their defensive readiness to attacking leafhoppers 3Deterring signals: Tobacco plants advertise their defensive readiness to attacking leafhoppers 4
Request Info...
2 ml SmartScan Racks...
... Immunogen: Partially purified chicken intestinal ... vitamin D receptor (VDR) from human, ... fish tissues. This antibody does ... receptors. MA1-710 detects both the ...
... The integration of 2D polyacrylamide gel ... widely regarded as a core technology platform ... resolving power for complex samples limited only ... resolve small and large proteins. Quantitative image ...
Biology Products: